// App-Quantinova.ai

OP0253 (2018) : A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis

Researchers

Presenter

  • R. Furie

Principal Investigators

  • M.A. Dooley

  • D. Wofsy

  • T. Takeuchi

  • A. Malvar

  • A. Doria

  • J. Romero-Díaz

  • T.M. Chan

  • A. Elegbe

  • G.B. Appel

  • D. Jayne

  • M.A. Maldonado

Medical Centers

  • Northwell Health, New York, NY

  • University of North Carolina, Chapel Hill, NC

  • University of California, San Francisco, San Francisco, CA

  • Teikyo University, Tokyo, Japan

  • Hospital Durand, Buenos Aires, Argentina

  • University of Pavia, Pavia, Italy

  • Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Columbia University Medical Center, New York, NY

  • University of Cambridge, Cambridge, UK

Locations

  • United States

  • Japan

  • Argentina

  • Italy

  • Mexico

  • Hong Kong

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • Lupus nephritis

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Mycophenolic acid

  • Prednisone

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved